title: [Comment of the Society of Pediatric and Adolescent Rheumatology on the US Food and Drug Administration (FDA) announcement regarding cases of malignancy in anti-TNF-treated patients].
authors.affiliation: Olgahospital-Kinderklinik, Stuttgart.
authors.forename: T
authors.initials: T
authors.lastname: Hospach
authors.forename: J P
authors.initials: JP
authors.lastname: Haas
authors.forename: H I
authors.initials: HI
authors.lastname: Huppertz
authors.forename: R
authors.initials: R
authors.lastname: Keitzer
authors.forename: H
authors.initials: H
authors.lastname: Michels
authors.forename: R
authors.initials: R
authors.lastname: Trauzeddl
authors.forename: D
authors.initials: D
authors.lastname: Föll
authors.forename: G
authors.initials: G
authors.lastname: Dannecker
authors.forename: G
authors.initials: G
authors.lastname: Horneff
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy*; D012219:Rheumatology; D012955:Societies, Medical; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha